Department of Hematology, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan.
Department of Gastroenterological Medicine, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan.
J Clin Pharm Ther. 2020 Aug;45(4):828-831. doi: 10.1111/jcpt.13146. Epub 2020 May 20.
5-Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS).
We herein report an 83-year-old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA.
We herein report as-yet-undescribed potential side effects, AZA-associated haemorrhagic enteritis that should be kept in mind.
5-氮杂胞苷（AZA）是一种广泛用于治疗骨髓增生异常综合征（MDS）的药物。
本报告介绍了一例 83 岁女性 MDS 患者接受 AZA 治疗。她耐受了 AZA 的第一个周期，但在第二个和第三个周期后出现了严重的不良反应，包括出血性肠炎和多发性肠溃疡。此外，AZA 给药间隔和血便出现时间随 AZA 周期而缩短。
我们报告了尚未描述的潜在副作用，即 AZA 相关的出血性肠炎，应引起注意。
